Wegener's Granulomatosis: the Current View
Overview
Affiliations
In the last few years, substantial progress has been achieved in elucidating the pathogenesis of Wegener's granulomatosis. Several genetic risk factors have been described. The structure of the granuloma and its possible function as ectopic lymphoid tissue have been defined. Furthermore, the consecutive immunopathological reactions leading to induction of PR3-antineutrophil cytoplasmic antibodies (ANCA) and the role of ANCA itself is getting clearer. However, the initial events leading to granuloma formation are still widely unknown. Concerning therapy, the significance of the so-called biological agents (TNF-alpha-blockers, Rituximab) still has to be defined.
Mousavi N, Molaei A, Alesaeidi S, Eftekhari Seas N, Effatpanah M Clin Pract Epidemiol Ment Health. 2024; 20:e17450179276345.
PMID: 38715951 PMC: 11075095. DOI: 10.2174/0117450179276345240117043037.
Wathurapatha W, Rathnamali B, Dissanayake U Case Rep Rheumatol. 2021; 2021:5353575.
PMID: 34751236 PMC: 8572124. DOI: 10.1155/2021/5353575.
All Consolidations are not Infective: Look Beyond ARDS.
Nizami M, Rohan M, Sharma A J Emerg Trauma Shock. 2019; 12(2):164-165.
PMID: 31198287 PMC: 6557056. DOI: 10.4103/JETS.JETS_96_18.
Ward N, Cosner D, Lamb C, Li W, Macknis J, Rooney M Case Rep Pathol. 2014; 2014:286030.
PMID: 25525543 PMC: 4265693. DOI: 10.1155/2014/286030.
Vordenbaumen S, Timm D, Bleck E, Richter J, Fischer-Betz R, Chehab G Rheumatol Int. 2010; 31(9):1251-4.
PMID: 21132301 DOI: 10.1007/s00296-010-1702-0.